Avidity Partners 13F holdings, Q1 2020
Holdings as of March 31, 2020 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 49 US equity positions worth $697.6m in its Q1 2020 13F filing. The largest position was SEATTLE GENETICS INC at 9.6% of the reported book, followed by MRK and ABBV. Against the Q4 2019 filing, it opened 30 new positions, added to 17 and reduced 2 among the top 49 holdings.
What did Avidity Partners own in Q1 2020? Top 49 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2019 |
|---|---|---|---|---|---|---|---|
| 1 | SEATTLE GENETICS INC | 9.6% | $66.9m | 580,000 | – | new | |
| 2 | MRK MERCK & CO. INC | Healthcare | 5.4% | $37.9m | 492,000 | – | new |
| 3 | ABBV ABBVIE INC | Healthcare | 5.2% | $36.3m | 477,000 | 407% | added |
| 4 | MCK MCKESSON CORP | Healthcare | 4.7% | $32.9m | 243,000 | – | new |
| 5 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 3.7% | $25.5m | 302,000 | – | new |
| 6 | REGN REGENERON PHARMACEUTICALS | Healthcare | 3.5% | $24.4m | 50,000 | – | new |
| 7 | CAH CARDINAL HEALTH INC | Healthcare | 3.5% | $24.2m | 505,000 | – | new |
| 8 | MIRATI THERAPEUTICS INC | 3.3% | $22.7m | 295,000 | 361% | added | |
| 9 | CATALENT INC | 3.1% | $21.4m | 411,000 | 347% | added | |
| 10 | MNTA MOMENTA PHARMACEUTICALS INC | 3.0% | $21.2m | 780,000 | 290% | added | |
| 11 | BIIB BIOGEN INC | Healthcare | 2.8% | $19.6m | 62,000 | – | new |
| 12 | EXEL EXELIXIS INC | Healthcare | 2.7% | $18.7m | 1,086,000 | – | new |
| 13 | BIOHAVEN PHARMACTL HLDG CO L | 2.6% | $18.4m | 540,000 | – | new | |
| 14 | ALEC ALECTOR INC | Healthcare | 2.5% | $17.2m | 714,000 | – | new |
| 15 | AUPH AURINIA PHARMACEUTICALS INC | Healthcare | 2.5% | $17.2m | 1,182,000 | 409% | added |
| 16 | CVS CVS HEALTH CORP | Healthcare | 2.4% | $16.4m | 277,000 | – | new |
| 17 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 2.2% | $15.1m | 357,000 | 561% | added |
| 18 | GILD GILEAD SCIENCES INC | Healthcare | 2.1% | $15.0m | 200,000 | – | new |
| 19 | XLRN ACCELERON PHARMA INC | 2.1% | $14.9m | 166,000 | – | new | |
| 20 | ALXN ALEXION PHARMACEUTICALS INC | 2.1% | $14.4m | 160,000 | – | new | |
| 21 | DVAX DYNAVAX TECHNOLOGIES CORP | 1.9% | $13.5m | 3,824,000 | 390% | added | |
| 22 | KDMN KADMON HLDGS INC | 1.7% | $11.8m | 2,828,000 | 241% | added | |
| 23 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.7% | $11.6m | 197,000 | – | new |
| 24 | CI CIGNA CORP NEW | Healthcare | 1.7% | $11.5m | 65,000 | 117% | added |
| 25 | UNIQURE NV | 1.6% | $11.2m | 237,000 | 331% | added | |
| 26 | MRNA MODERNA INC | Healthcare | 1.6% | $10.9m | 365,000 | – | new |
| 27 | HUM HUMANA INC | Healthcare | 1.5% | $10.4m | 33,000 | – | new |
| 28 | HORIZON THERAPEUTICS PUB LTD | 1.4% | $9.9m | 333,000 | 122% | added | |
| 29 | CHEMOCENTRYX INC | 1.4% | $9.5m | 236,000 | – | new | |
| 30 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.2% | $8.5m | 98,000 | 197% | added |
| 31 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 1.2% | $8.1m | 34,000 | -15% | reduced |
| 32 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 1.1% | $7.8m | 80,000 | – | new |
| 33 | LGND LIGAND PHARMACEUTICALS INC | Healthcare | 1.1% | $7.4m | 102,000 | – | new |
| 34 | IRWD IRONWOOD PHARMACEUTICALS INC | Healthcare | 1.1% | $7.4m | 735,000 | – | new |
| 35 | VSTM VERASTEM INC | Healthcare | 1.1% | $7.4m | 2,790,698 | – | new |
| 36 | CRL CHARLES RIV LABS INTL INC | Healthcare | 1.0% | $7.2m | 57,000 | – | new |
| 37 | ALLERGAN PLC | 1.0% | $7.1m | 40,000 | – | new | |
| 38 | AERIE PHARMACEUTICALS INC | 1.0% | $6.8m | 507,000 | – | new | |
| 39 | ASND ASCENDIS PHARMA A S | Healthcare | 1.0% | $6.8m | 60,000 | 43% | added |
| 40 | IMMU IMMUNOMEDICS INC | 1.0% | $6.6m | 493,000 | 252% | added | |
| 41 | ESPERION THERAPEUTICS INC NE | 0.9% | $6.5m | 205,000 | 57% | added | |
| 42 | CHRS COHERUS BIOSCIENCES INC | Healthcare | 0.9% | $6.2m | 382,000 | 78% | added |
| 43 | AIMT AIMMUNE THERAPEUTICS INC | 0.8% | $5.9m | 408,000 | – | new | |
| 44 | ANIK ANIKA THERAPEUTICS INC | Healthcare | 0.7% | $4.9m | 168,000 | – | new |
| 45 | BTAI BIOXCEL THERAPEUTICS INC | 0.7% | $4.7m | 211,000 | – | new | |
| 46 | AVADEL PHARMACEUTICALS PLC | 0.4% | $3.0m | 382,000 | – | new | |
| 47 | NERV MINERVA NEUROSCIENCES INC | Healthcare | 0.4% | $2.7m | 444,200 | – | new |
| 48 | SUNESIS PHARMACEUTICALS INC | 0.3% | $1.8m | 4,310,000 | 208% | added | |
| 49 | COLL COLLEGIUM PHARMACEUTICAL INC | Healthcare | 0.0% | $278.0k | 17,000 | -91% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.